Perrigo Company PLC
NYSE:PRGO

Watchlist Manager
Perrigo Company PLC Logo
Perrigo Company PLC
NYSE:PRGO
Watchlist
Price: 24.6 USD 2.29%
Market Cap: 3.4B USD

Perrigo Company PLC
Investor Relations

Perrigo Company PLC, a stalwart in the pharmaceutical and healthcare sectors, has carved a niche by specializing in over-the-counter (OTC) health and wellness products. This Dublin-based company traces its origins back to 1887, in Allegan, Michigan, where it began as a modest packager of home remedies. Over the decades, Perrigo has evolved into a global powerhouse that provides affordable and quality healthcare products, distributing them across various markets around the world. Its strategy hinges on delivering effective OTC solutions and a wide array of consumer self-care products, making it a familiar presence in households seeking reliable alternatives to more expensive brand-name pharmaceuticals.

Perrigo's business model is centered on offering value to both consumers and retailers. By producing generic versions of well-known drugs, it captures a significant share of the market driven by cost-conscious customers. This approach also involves collaborating with retail giants to supply their private label OTC medications, a mutually beneficial arrangement that allows retailers to offer lower-cost alternatives under their own brands while maintaining healthy margins. Beyond just OTC medications, Perrigo has expanded its offerings to include nutritional products and topical solutions, further diversifying its portfolio and revenue streams. The company's consistent investment in innovation and keen attention to regulatory compliance underscore its commitment to quality and safety, attributes that resonate well in an industry guided by trust and efficacy.

Show more
Loading

Earnings Calls

2024 Q3
Nov 6, 2024
Show Transcript
Previous
Next
Perrigo's Q3 Performance Shows Growth Amid Challenges
2024 Q3
Nov 6, 2024

Perrigo reported a 3.2% decrease in net sales for Q3 but achieved a notable 27% growth in EPS to $0.81. The infant formula sector showcased significant revival, with sales increasing 3% year-over-year and 58% sequentially. Strong gross margin expansion of 160 basis points to 41% was driven by cost-saving initiatives, with a projected $140 million to $170 million in annual savings by 2026. Looking ahead, the company reaffirmed its 2024 EPS guidance at $2.50 to $2.65, while expected operating margins suggest a continued path towards recovery and stabilization.

Show Full Analysis

Management

Mr. Patrick Lockwood-Taylor
President, CEO & Director
No Bio Available
Mr. Eduardo Guarita Bezerra
Executive VP & CFO
No Bio Available
Mr. Ronald C. Janish
Chief Transformation Officer and Executive VP of Global Operations & Supply Chain
No Bio Available
Ms. Kyle L. Hanson
Advisor
No Bio Available
Mr. Shannon Hukill
Senior Director of Technical Operations
No Bio Available
Ms. Alison Ives
Executive VP & Chief Scientific Officer
No Bio Available
Mr. Bradley Joseph
Vice President of Global Investor Relations & Corporate Communications
No Bio Available
Mr. Charles Atkinson
Executive VP, General Counsel & Secretary
No Bio Available
Ms. Mary Reilly-Brest
Director of Global Organizational and Human Resource Development
No Bio Available

Contacts

Address
DUBLIN
DUBLIN
The Sharp Building, Hogan Place, Dublin 2
Contacts
+35317094000.0
www.perrigo.com